Clinical Trial Update: Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

This update covers the Phase 2 evaluation of BAY 59-8862 in taxane-resistant non-small cell lung cancer, noting that the trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BAY 59-8862

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED